Variable	Confirmed case N = 60	Not confirmed N = 36	p-valu
HIV status, n (%)			<0.00
Person with HIV	13 (22%)	1 (2.8%)	
Person without HIV	37 (62%)	35 (97%)	
Unknown	10 (17%)	0 (0%)	
ever hospitalized, n (%)			0.2
Yes	53 (88%)	28 (78%)	
No	7 (12%)	8 (22%)	
Unknown	0 (0%)	0 (0%)	
Length of hospitalization, Median (Q1, Q3)	9 (6, 13)	5 (4, 10)	0.015
Missing/Unknown	7	8	
Escalation of care, n (%)			>0.9
Yes	1 (1.9%)	1 (3.6%)	
No	52 (98%)	27 (96%)	
Unknown	0 (0%)	0 (0%)	
Missing/Unknown	7	8	
supplemental oxygen, n (%)			0.6
Yes	0 (0%)	1 (3.6%)	
No	52 (98%)	27 (96%)	
Unknown	1 (1.9%)	0 (0%)	
Missing/Unknown	7	8	
receive nasogastric fluids, n (%)			>0.9
Yes	0 (0%)	0 (0%)	
No	60 (100%)	36 (100%)	
Unknown	0 (0%)	0 (0%)	
receive IV fluids during course monkeypox infection, n (%)			0.4
Yes	5 (8.3%)	1 (2.8%)	
No	55 (92%)	35 (97%)	
Unknown	0 (0%)	0 (0%)	
receive analgesia for pain management, n (%)			0.003
Yes	33 (55%)	8 (22%)	
No	27 (45%)	28 (78%)	
Unknown	0 (0%)	0 (0%)	
receive antibiotics during course monkeypox infection, n (%)			>0.9
Yes	56 (93%)	33 (92%)	
No	4 (6.7%)	3 (8.3%)	
Unknown	0 (0%)	0 (0%)	
receive antifungals during course monkeypox infection, n (%)		·	>0.9

ariable	Confirmed case N = 60	Not confirmed N = 36	p-value
Yes	1 (1.7%)	0 (0%)	
No	59 (98%)	36 (100%)	
Unknown	0 (0%)	0 (0%)	
xperimental antiviral during course monkeypox infection, n ($^{\circ}$	6)		>0.9
Yes	0 (0%)	0 (0%)	
No	60 (100%)	36 (100%)	
Unknown	0 (0%)	0 (0%)	